Business Wire

CA-TREASURE-DATA

8.10.2020 14:02:14 CEST | Business Wire | Press release

Share
Treasure Data Unveils Global Partner Program to Meet Demand for Enterprise Customer Data Platforms

Treasure Data ™ today unveiled its Global Partner Program , offering agencies, consultancies, technology service providers, independent software vendors (ISVs) and data specialists new certifications, training, and technical, marketing and sales support for the Company’s market-leading Customer Data Platform (CDP). The program will be launching with 20 strategically selected partners and is set to grow as we continue to expand our customer base in all territories.

“Enterprises are turning to trusted partners in their respective industries to accelerate customer-centric digital transformation and solve complex data, scale and other obstacles that hinder exceptional brand experiences,” said Stephen Lee, Vice President of Strategy and Business Development, Treasure Data. “Treasure Data’s Global Partner Program helps trusted enterprise partners expand their CDP technical acumen and experience to grow their market and revenue opportunities.”

Certified Partners help customers throughout their entire CDP deployment journey. For agencies, and consultancies, the program offers three tiers—bronze, silver and gold—with level-specific commitments for online training, joint marketing, market development funds (MDF), discounts, and technical and sales support. In addition to access to Treasure Data’s CDP Academy training, partners may also receive additional certified sales and technical training matched to key roles ranging from sales and marketing operations to data architects and scientists. The program is also open to select Treasure Data technology partners.

“Acxiom and its partners strive to drive transformational change for clients through strategic partnerships and we’re excited to be working with such a powerful tool as the Treasure Data CDP,” says Mike Menzer, President, Acxiom International. “Customer Data Platforms are creating a lot of growth right now and we see the Acxiom and Treasure Data combination as a key solution to driving value for our clients.”

“CDPs like Treasure Data are playing an increasingly important role in helping marketers better understand who their customers are,” says Jayne Babine, Executive Vice President, Partnerships and Sales at MightyHive. “As one of the leading full-service global marketing services firms, MightyHive is thrilled to be partnering with Treasure Data to make our clients more successful around data marketing strategy and execution.”

Treasure Data’s CDP unifies and unlocks the full potential of customer data. It captures all online and offline customer interactions as they happen, helping companies to understand all brand interactions with the precise detail needed to engage customers at the right time in the right place. Trusted by more than 400 organizations worldwide, Treasure Data provides an enterprise-scale, independent solution that lets partners work with any existing technology stack and gives them the flexibility to ingest all types of data. This makes it easy to integrate the Treasure Data CDP with partner offerings and preferred solutions stacks to accelerate the delivery of outstanding, personalized data-driven brand experiences.

Partners included in Treasure Data’s Global Partner Program: Accenture, Acxiom, MightyHive in the Gold Tier. Allant, BitBang, Brain+Trust Partners, Merkle (Isobar, Sokrati) Search Discovery, SilverBullet in the Silver Tier. AdGlobal360, Ansira, Exostatic, Gravitai, Green Lyzard, HGS Digital, Hero Digital, Hexagon Data, Keyrus, Verticurl in the Bronze Tier. For more information on our partner program, please visit https://www.treasuredata.com/partnerships/

About Treasure Data

Treasure Data Customer Data Platform (CDP) empowers enterprises by delivering rich insights that drive outstanding customer experiences. Built on a strong data management foundation, our CDP enables brands to securely unify customer data across silos at scale so they can better identify, engage and acquire customers. The highly configurable platform boasts a comprehensive connector network that evolves with your existing technology stack to future-proof all customer data initiatives. Treasure Data has more than 400 customers including Fortune 500 and Global 2000 enterprises, and is a wholly-owned subsidiary of Arm Ltd.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye